Repertorio delle ricerche di eccellenza

The regulation of protein levels and function, which may define the phenotype of a cancer cells, occurs at many levels including transcription, translational regulation, and posttranslational modifications. The development of reliable proteomic is crucial for the more global understanding of cancer cell physiology and phatogenesis at protein levels. A number of tumor models have identified several key cellular signaling pathways that work independently, in parallel, and/or through interconnections to promote cancer development. Since detailed information at post-translational level are expected to clarify mechanisms involved in chemotherapeutic resistance, a targeted therapeutic approach evaluated by preclinical studies of molecules in the R&D pipelines of drug companies, will aim to improve the actual therapeutic approach toward patients with hematological malignancies (HM). We presented here the results of our last five years research, including the novel under establishing tuning of these studies, by the Reverse Phase Protein Array (RPPA), a screening approach enable to generate in Italy a comprehensive protein and phosphor-protein signature of large patient populations affected by HM.